Clover Biopharmaceuticals Receives FDA Approval for SCB-1019 RSV Vaccine Trial
China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) has announced receiving clinical approval from the US Food...
AIM Vaccine’s mRNA-based Shingles Vaccine Receives FDA Approval for Clinical Study
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving approval from the US Food...
NMPA Updates Rules on Domestic Production of Imported Medical Devices
The National Medical Products Administration (NMPA) has released a notification on further adjusting and optimizing...
Broncus Medical’s BroncQCT Approved by Zhejiang Administration for China Market Entry
Broncus Medical Inc., a provider of precision intervention solutions for lung diseases with operations in...
Lifetech Scientific’s LAmbre Plus LAA Closure System Gains US Medical Insurance Coverage
China-based Lifetech Scientific Corporation (HKG: 1302) has announced obtaining medical insurance coverage in the United...
Hansoh Pharmaceutical Reports 21% Revenue Growth, Boosted by Innovative Drugs
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) released its 2024 financial report last week,...
Johnson & Johnson Pledges USD55 Billion for US Expansion, Focusing on Manufacturing and R&D
US giant Johnson & Johnson (J&J, NYSE: JNJ) has committed to investing over USD 55...
FDA Issues Second CRL to Hengrui’s Camrelizumab Combo Due to Manufacturing Issues
The US Food and Drug Administration (FDA) last week issued another complete response letter (CRL)...
AbbVie Sues Genmab Over Alleged Trade Secret Misappropriation in ADC Development
US pharmaceutical giant AbbVie (NYSE: ABBV) has filed a lawsuit in the U.S. District Court...
Shanghai Junshi Biosciences’ Loqtorzi Approved for Hepatocellular Carcinoma Treatment
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced receiving approval from the...
Shanghai Pharmaceuticals Subsidiary Fined USD23 Million for Anti-Monopoly Violations
China’s Shanghai Pharmaceuticals (SPH, HKG: 2607, SHA: 601607) has disclosed that its subsidiary, Shanghai SINE...
HutchMed’s Tazverik Receives Conditional Approval from China’s NMPA for Lymphoma Treatment
China-based HutchMed (NASDAQ: HCM, HKG: 0013) has announced receiving conditional marketing approval from the National...
Shenzhen Kangtai Partners with AstraZeneca to Establish Vaccine JV in Beijing
China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has formed a vaccine-focused partnership with...
Syneron Bio Collaborates with AstraZeneca to Develop Macrocyclic Peptides for Chronic Diseases
China-based Syneron Bio, a biotech firm specializing in macrocyclic peptide drugs, has entered into a...
Hainan Poly Pharm Faces Delisting After CSRC Imposes Strict Penalties for Financial Misconduct
China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) was imposed strict administrative penalties by the...
AstraZeneca Unveils USD2.5 Billion Beijing R&D Center Plan Amid Strategic China Partnerships
UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) has announced a five-year plan to invest USD 2.5...
Innovent Biologics Doses First Patient with IBI354 in HeriCare-Ovarian01 Study
China-based Innovent Biologics, Inc. (HKG: 1801) has administered the first dose of its antibody-drug conjugate...
Everest Medicines’ EVM14 mRNA Cancer Vaccine Clears US FDA IND Application
China-based Everest Medicines (HKG: 1952) has announced that its Investigational New Drug (IND) application for...
Harbour BioMed Partners with AstraZeneca on Multi-Specific Antibody Development
China-based Harbour BioMed (HKG: 2142) has formed a strategic partnership with UK pharmaceutical giant AstraZeneca...
CSPC Pharmaceutical Group Gains NMPA Approval for SYS6040 Clinical Trial
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving approval from the National Medical...